Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Redux

This article was originally published in The Tan Sheet

Executive Summary

Redux: Prescription anti-obesity drug approved by FDA on April 29. Wyeth-Ayerst and Interneuron will introduce the product in June 1996. The cost of Redux (dexfenfluramine) to the patient will be approximately $2.40 per day. It will be available in 15 mg capsules, to be taken twice daily. Redux is scheduled by the Drug Enforcement Agency as Category IV, meaning "low potential for abuse." Prescription restrictions for Category IV drugs allow "up to five renewals" within a six month period. Weight loss company Jenny Craig is planning a test program using Redux in at least one market when the compound becomes available...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS085358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel